Neuronetics, Inc.

Overview

This report applies William J. O'Neil's CAN SLIM methodology to Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated neurohealth medical technology company that markets the NeuroStar Advanced Therapy TMS system and operates the Greenbrook TMS clinic network. The analysis evaluates STIM against O'Neil's seven growth-stock criteria—Current quarterly earnings, Annual earnings, New catalysts, Supply/demand, Leader/Laggard status, Institutional sponsorship, and Market direction—to determine whether the stock fits the profile of a winning growth stock at the current price of $1.27 (as of June 24, 2026).

Financial and Business Overview

Neuronetics is a commercial-stage medical technology company headquartered in Malvern, PA, that designs and markets the FDA-cleared NeuroStar Advanced Therapy System for transcranial magnetic stimulation (TMS) treatment of major depressive disorder, OCD, anxious depression, and adolescent MDD. Following the December 2024 acquisition of Greenbrook TMS, STIM transitioned from a pure-play device company into a vertically integrated mental health platform operating 93 clinics nationwide alongside its NeuroStar device business. FY2025 revenue reached $149.2 million (up 99% as reported, +15% adjusted pro forma), but the company posted a net loss of $39.1 million ($0.59/share). Q1 2026 revenue was $34.5 million (+8% YoY) with a net loss of $10.8 million ($0.16/share). The balance sheet is precarious: $13.2 million cash and $5.8 million restricted cash against $65 million total debt as of 3/31/2026, with shareholders' equity of only $13.3 million and accumulated deficit of $469.6 million. ROE for FY2025 was approximately -174%. Management guides FY2026 revenue of $160–166M and operating cash flow of negative $13–17M, with positive operating cash flow targeted for H2 2026.

Market Position & Competitive Advantages

Neuronetics holds the leading market position in TMS therapy with the largest installed base (800+ U.S. customer sites), 245,000+ patients treated, 8.8 million treatment sessions, and the industry's largest real-world outcomes database (TrakStar). Key competitive moats include: (1) FDA clearances across multiple indications including adolescent MDD (15–21), OCD, and anxious depression; (2) broad reimbursement coverage—104+ private insurers plus federal programs covering ~95% of insured U.S. lives; (3) vertical integration via the Greenbrook clinic network (93 centers across 49 states); (4) 60+ issued patents; and (5) an emerging partnership with Compass Pathways to deliver COMP360 psilocybin therapy for TRD upon expected FDA approval. Honest risks: BrainsWay, MagVenture, Magstim, and Nexstim have all closed the FDA-indication gap (including adolescent MDD); Flow Neuroscience's at-home tDCS headset disrupts the in-clinic model; pharmaceutical alternatives and SPRAVATO compete for the same TRD population; and the clinic business operates at ~30% gross margins versus 75%+ for legacy device sales, structurally compressing overall margins from 72% (2024) to 48.5% (2025).

Stock Performance

STIM stock action is unequivocally bearish and exhibits the chart pattern of a broken-down laggard, not a CAN SLIM leader. Current price of $1.27 sits 74% below the 52-week high of $4.85 and only 58% above the 52-week low of $0.80. The stock is down 64.3% over the trailing year. Price trades below both the 50-day moving average ($1.46, -13.5%) and the 200-day moving average ($1.84, -31.2%), confirming a sustained downtrend with both moving averages sloping downward. Average daily volume of 2.23 million shares on 10-day volume of only 1.1 million shows decelerating interest. Market cap is microcap at $88 million on 69.6 million shares outstanding. The 14.12% activist stake by Jorey Chernett (April 2026) calling for a sale of the TMS business has not catalyzed any meaningful rally, suggesting institutional skepticism remains pervasive.

CAN SLIM Analysis

Key Risks

Conclusion

Under strict CAN SLIM discipline, Neuronetics fails virtually every test William O'Neil established for identifying winning growth stocks. The company has no positive quarterly EPS (fails C), no annual earnings track record over five years and a deeply negative ROE of -174% (fails A), trades 74% below its 52-week high rather than near new highs (fails the most important 'N' criterion), is being actively diluted via ATM and secondary offerings rather than exhibiting tight supply (fails S), is among the worst-performing laggards in the medical device space down 64% YoY (fails L), and lacks quality institutional sponsorship—its largest independent holder is an activist demanding a breakup (fails I). While there are genuine fundamental positives—leading TMS market share, broad reimbursement, the Compass Pathways optionality, new CEO Dan Reuvers, and narrowing operating losses—O'Neil's methodology is explicit: buy strength, not turnarounds; buy leaders, not laggards; buy stocks emerging from sound bases near new highs, not stocks in confirmed downtrends with going-concern risk. STIM may eventually prove to be a successful deep-value or special-situation play (particularly if the activist-led strategic review yields a sale), but that thesis belongs to a Graham-style framework, not CAN SLIM. For growth investors following O'Neil's discipline, STIM is a clear AVOID/SELL at $1.27, and would only become actionable upon a confirmed base breakout above the 200-day moving average accompanied by demonstrable cash flow inflection.

Overview

This is a Druckenmiller-style macro analysis of Neuronetics (STIM), examining the company’s vertical integration gamble, its liquidity trap, and the potential for an activist‑driven breakup to unlock substantial asymmetric value. The thesis hinges on the interplay between a looming debt covenant cliff, a powerful secular tailwind in interventional psychiatry, and self‑reinforcing positive feedback that could emerge from a strategic sale of the TMS business.

Macro Context

The U.S. economy shows late‑cycle characteristics: resilient employment but tightening credit conditions, elevated treasury yields, and a Fed sidelined by sticky inflation. In this environment, capital is being rationed to unprofitable micro‑cap companies with leveraged balance sheets. Secularly, mental health is undergoing a generational shift toward non‑pharmacological, interventional treatments (TMS, esketamine, and psychedelics) supported by expanding insurance coverage (Optum/UHC now allowing nurse practitioners to deliver TMS) and a White House executive order fast‑tracking psychedelic therapy reviews. This creates a powerful macro tailwind for companies that can survive to capture the adoption curve.

Company Position in Macro Landscape

STIM is both a beneficiary of the secular mental health theme and a victim of the current credit squeeze. Its integrated model—combining the market‑leading NeuroStar TMS device with the Greenbrook clinic chain—gives it a unique end‑to‑end position in interventional psychiatry. However, the debt‑fueled acquisition has left the company with $65 M in borrowings and a looming covenant breach by March 2027, placing its survival at the mercy of lender Perceptive Advisors. The macro environment rewards simple, asset‑light, profitable business models (like BrainsWay), while punishing complex, cash‑burning structures. STIM’s current integrated form is a poor fit for the tightening credit cycle, but its underlying assets are deeply undervalued relative to peers.

Reflexivity Analysis

The stock is locked in a vicious reflexive loop: a sub‑$1.50 share price impairs equity‑raising capacity, intensifies going‑concern fears, and lowers confidence among customers and employees, which in turn pressures revenue and makes the covenant breach more likely. This self‑fulfilling prophecy can only be broken by an exogenous shock—enter the activist campaign by Jorey Chernett (14.12% holder), who has publicly demanded a sale of the TMS business. If the board engages in a credible strategic review, the reflexivity can flip: the prospect of a breakup would force the market to re‑value the parts on a sum‑of‑the‑parts basis, quickly lifting the stock toward a price that reflects potential proceeds. The new CEO’s deliberate “open mind” comments signal that management is not blocking this path, which could trigger a positive feedback loop if the market begins to price in a transaction.

Competitive Position & Disruptive Threats

STIM’s NeuroStar TMS device possesses an unrivaled clinical dataset (over 5 million treatments) and broad FDA clearances. The Greenbrook network of 93 clinics gives it a national platform for therapy delivery (SPRAVATO, and eventually psilocybin) that pure‑play device peers lack. However, as a combined entity, it is underinvesting in the device business, allowing BrainsWay (trading at 8.4x forward sales, profitable) to outgrow it. At‑home tDCS devices (Flow Neuroscience) and psychedelic therapies (COMPASS Pathways) could disrupt the TMS treatment model over the longer term. The real competitive moat lies in the integrated clinic infrastructure for complex drug‑device therapies. Divorcing the device business would allow the clinic platform to focus on that advantage while the device business could be sold to a strategic buyer that can properly resource its growth.

Asymmetric Risk/Reward

The payoff profile is highly convex. At $1.28, the equity is option‑like, deeply out‑of‑the‑money due to solvency risk. The activist thesis implies equity value could be 5‑7x the current price if the TMS business is sold at a conservative 4x revenue (~$280 M) and the clinic business is valued at peer multiples (≥4.9x EV/clinic), with excess proceeds used to retire all debt and pay a special dividend. Even a friendly restructuring that only avoids default could still re‑rate the stock to 1‑2x sales on improved liquidity. Downside is 100% if Perceptive accelerates the loan. The optionality created by the activist letter and the new CEO’s openness to strategic alternatives was not present when the stock fell below $1. To a macro opportunist, a small allocation with a defined stop‑loss represents a classic heads‑I‑win‑big, tails‑I‑lose‑my‑premium bet.

Key Risks

Investment Details